SOLV

Based on Solventum Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Solventum do?

Solventum is a healthcare company that develops and sells medical, dental, health information, and filtration products. It operates four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company serves hospitals, clinicians, dental practices, and life sciences customers globally.

Does SOLV pay dividends?

No, Solventum does not currently pay a dividend. As a recently spun-off company, it is focused on managing its balance sheet and investing in its core operations rather than distributing cash to shareholders at this stage.

When does SOLV report earnings?

Solventum reports on a quarterly cadence, as is standard for US-listed large-cap companies. For exact dates and the most recent results, check Solventum's investor relations page, where management also provides segment-level commentary.

Is SOLV a good stock to buy?

UQS Score rates SOLV as Below Average overall. The Valuation pillar is Attractive and Quality is Good, but Moat and Growth are both Weak. Whether it fits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.

Is SOLV overvalued?

Based on the UQS Valuation pillar, SOLV is rated Attractive — suggesting it may be trading at a discount relative to its fundamental profile. However, an attractive price alone does not offset concerns around weak competitive moat and limited growth momentum.

How does SOLV compare to its competitors?

Solventum competes in a broad healthcare space alongside companies like Fresenius Medical Care, Universal Health Services, and The Ensign Group. Unlike pure-play service providers, Solventum's differentiation lies in its multi-segment product and software portfolio, though its Moat pillar rating suggests this differentiation is currently limited.

What is SOLV's market cap bracket?

Solventum is classified as a large-cap company. This places it among established healthcare businesses with significant revenue scale, though it is still early in its journey as an independent publicly traded entity.

Who founded Solventum?

Solventum was not founded in the traditional sense — it was spun off from 3M Company as an independent healthcare business. It was incorporated in 2023 and began trading publicly in 2024. More detail on its corporate history is available through Solventum's investor relations materials.

Is SOLV a long-term quality investment?

As a long-term quality indicator, SOLV's UQS profile presents a mixed picture. The Good Quality rating is a positive signal, but Weak Moat and Weak Growth suggest the company needs to demonstrate stronger competitive positioning before it can be considered a high-conviction long-term holding.

What is the main competitive advantage of Solventum?

Solventum's breadth across medical, dental, software, and filtration segments gives it cross-selling potential and diversified revenue streams. However, the UQS Moat pillar is currently rated Weak, indicating that this diversification has not yet translated into durable competitive advantages relative to sector peers.

What sector does SOLV belong to?

Solventum operates in the Healthcare sector. Within that sector, it spans medical devices, dental products, health IT software, and filtration technologies — making it a diversified healthcare solutions company rather than a single-category specialist.

Is SOLV a growth stock or value stock?

Based on the UQS pillar profile, SOLV leans toward value territory — the Valuation pillar is Attractive while the Growth pillar is Weak. This combination suggests the stock may appeal more to value-oriented investors than those seeking high-growth compounders.

Solventum Corporation currently shows below-average quality metrics, suggesting challenges with profitability.

Solventum Corporation faces growth headwinds with declining or stagnant revenue trends.

Solventum Corporation has some risk factors including moderate leverage or solvency concerns.

Solventum Corporation appears expensively valued relative to its fundamentals and growth prospects.

Solventum Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SOLV.

The UQS (Unified Quality Score) for Solventum Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Solventum Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Solventum Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.